Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD).

Autor:	Ellis J; Department of Life Sciences, University of Bath, Bath, UK.; Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK., McHugh N; Department of Life Sciences, University of Bath, Bath, UK., Pauling JD; Department of Life Sciences, University of Bath, Bath, UK.; Department of Rheumatology, North Bristol NHS Trust, Westbury on Trym, UK., Bruce IN; Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK., Charlton R; Department of Life Sciences, University of Bath, Bath, UK., McGrogan A; Department of Life Sciences, University of Bath, Bath, UK., Skeoch S; Department of Life Sciences, University of Bath, Bath, UK sarah.skeoch1@nhs.net.; Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
Jazyk:	angličtina
Zdroj:	Lupus science & medicine [Lupus Sci Med] 2024 Jul 27; Vol. 11 (2). Date of Electronic Publication: 2024 Jul 27.
DOI:	10.1136/lupus-2024-001213
Abstrakt:	Objective: To obtain updated estimates on the incidence and prevalence of systemic lupus erythematosus (SLE) in the UK, over the period 1990-2020, using the Clinical Practice Research Datalink (CPRD). Methods: This was a retrospective cohort study using the CPRD covering the period 1990-2020. A case ascertainment algorithm was developed in line with best practice recommendations for observational research. Incidence was calculated per 100 000 person-years and point prevalence (at the mid-year point) calculated per 100 000. Results were stratified by sex. Results: 9443 SLE cases were identified. 5278 incident cases were identified (4538 women, 740 men). The overall incidence rate was 5.47 (95% CI 5.33 to 5.62) cases per 100 000 person-years. Incidence rates decreased slightly across the study period, which was more pronounced for women than men. Point prevalence increased over time, from 21.4 (95% CI 17.68 to 25.67) per 100 000 in 1990 to 107.14 (95% CI 103.26 to 111.12) per 100 000 in 2020. Conclusions: The observed fivefold increase in prevalence of SLE over the last 30 years, in the context of a modest decline in incidence rate, may suggest improved outcomes in SLE and has important implications for healthcare service delivery and planning in the UK. Competing Interests: Competing interests: JDP has undertaken consultancy work and/or received speaker honoraria from Janssen, Astra Zeneca, Boehringer Ingelheim, IsoMab, Sojournix Pharma and Permeatus Inc. INB has received grant support from GSK, Janssen and Astra Zeneca; consulting fees from AstraZeneca, Eli Lilly, GSK, Takeda, UCB and Dragonfly Therapeutics; and was a speaker for AstraZeneca, Janssen, GSK and UCB. The remaining authors declare no conflicts of interest. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu